1. DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies. (25th January 2019) Authors: Chiorean, M; Su, C; Matsuoka, K; Orlando, A; Thorpe, A J; Nduaka, C I; Chapman, D S; Woodworth, D A; Lawendy, N; Friedman, G S; Cohen, R D Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P619 Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission. (25th January 2019) Authors: Rubin, D T; Travis, S; Abraham, B P; Su, C; Lawendy, N; Fan, H; Woodworth, D A; Thorpe, A J; Nduaka, C I; Quirk, D; Reinisch, W Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP43 Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders. (25th January 2019) Authors: Rubin, D T; Dubinsky, M C; Lukas, M; Quirk, D; Nduaka, C I; Maller, E; Lawendy, N; Kayhan, C; Fan, H; Woodworth, D A; Chan, G; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S050 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P388 Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme. (25th January 2019) Authors: Farraye, F A; Qazi, T; Kotze, P G; Moore, G T; Kayhan, C; Mundayat, R; Maller, E; Su, C; Soonasra, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS. (15th March 2019) Authors: Sandborn, W J; Panés, J; Panaccione, R; D'Haens, G; Sands, B E; Su, C; Moscariello, M; Jones, T V; Pedersen, R D; Friedman, G S; Lawendy, N; Chan, G Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 2(2019)Supplement 2 Page Start: 396 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P685 Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials. (25th January 2019) Authors: Dubinsky, M C; Bressler, B; Armuzzi, A; Salese, L; DiBonaventura, M; Maller, E; Fan, H; Woodworth, D A; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S462 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P466 Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials. (25th January 2019) Authors: Sandborn, W J; Panés, J; Panaccione, R; D'Haens, G R; Sands, B E; Su, C; Moscariello, M; Jones, T V; Pedersen, R D; Friedman, G S; Lawendy, N; Chan, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Design of piezoelectric self-sensing microinjection device. (April 2019) Authors: Wei, X W; Sun, L P; Su, C; Shi, Y L; Li, J Q Journal: Journal of physics Issue: Volume 1209(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P712 Tofacitinib efficacy in patients with moderate to severe ulcerative colitis: Subgroup analyses of OCTAVE Induction 1 and 2 and OCTAVE Sustain by 5-aminosalicylates use. (25th January 2019) Authors: Hanauer, S; Rubin, D T; Gionchetti, P; Su, C; Woodworth, D A; Quirk, D; Salese, L; Wang, W; Marren, A; Lawendy, N; Panaccione, R Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S477 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P531 Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment. (25th January 2019) Authors: Reinisch, W; Osterman, M T; Doherty, G; Marren, A; Woodworth, D A; Lawendy, N; Kwok, K; Maller, E; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗